We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > TAK-888

News List

Takeda, CSL-led plasma players band together on COVID-19 fiercebiotech
April 13, 2020
There’s more than one way to skin a cat. And in the race to create a plasma-based treatment for COVID-19, industry leaders have decided the best way is to join forces.
Development initiated for a plasma-derived COVID-19 therapy europeanpharmaceuticalreview
March 10, 2020
An anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) is being developed to treat infected, high-risk individuals with COVID-19.
Takeda initiates development of a plasma-derived therapy for COVID-19 expresspharma
March 05, 2020
Anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) being developed to treat infected, high-risk individuals with COVID-19.